GU Cancer

HERO compares androgen deprivation therapies in prostate cancer

An oral androgen deprivation therapy (ADT) taken once daily maintained castrate levels of testosterone at a higher rate and was associated with lower risk of major adverse cardiovascular events (MACE) in men with advanced prostrate cancer compared to a standard care injectable ADT, a phase III trial found. Data from the HERO trial presented at ...

Already a member?

Login to keep reading.

© 2021 the limbic